Parkinson's Disease, Diagnostic Observations (PADDO) (PADDO)
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT01249768|
Recruitment Status : Unknown
Verified March 2016 by Marjolein Aerts, Radboud University.
Recruitment status was: Recruiting
First Posted : November 30, 2010
Last Update Posted : March 31, 2016
Parkinson's Disease and the Atypical Parkinsonian Disorder (like Multiple System Atrophy, Progressive Supranuclear Palsy, Corticobasal Degeneration, Lewy Body Dementia) are disease entities with partly common symptomatology. Especially very early in the course of disease, the differentiation between both disease entities can be challenging, even for specialists in the field of movement disorder. However, the establishment of a correct diagnosis is very important for adequate patientcounseling, treatment and the correct inclusion of patients in research trials. Ancillary diagnostic investigations are looked upon to aid in this diagnostic dilemma.
To investigate the value of ancillary diagnostic investigations, more specific MRI, analysis of cerebrospinal fluids and a second opinion in a specialized movement disorder centre, to differentiate Parkinson's disease and the Atypical Parkisonisonian disorder.
|Condition or disease|
|Parkinson's Disease Atypical Parkinsonism|
|Study Type :||Observational|
|Estimated Enrollment :||150 participants|
|Official Title:||Observational Study Assessing the Diagnostic Contribution of 3-Tesla MRI, CSF Analysis and a Second Opinion in a Specialized Movement Disorder Centre, in Differentiating Between Parkinson's Disease and Atypical Parkinsonism|
|Study Start Date :||July 2010|
|Estimated Primary Completion Date :||July 2017|
|Estimated Study Completion Date :||July 2018|
The cohort will consist of 150 patients with a hypokinetic rigid syndrome and a disease duration of maximum 36 months
- percentage of correct diagnosis for each of the specified ancillary investigations [ Time Frame: 36 months ]Percentage of correct diagnosis for each of the specified ancillary investigations to differentiate between either PD or atypical parkinsonism
- Percentage of correct diagnosis for each of the specified ancillary investigations [ Time Frame: 36 months ]Percentage of correct diagnosis for each of the specified ancillary investigations(MRI, CSF analysis, and second opinion) to differentiate between the specific diagnosis (PD, MSA, PSP, CBD, LBD, VaP)
Biospecimen Retention: Samples With DNA
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01249768
|Contact: B Bloem, Prof, MDemail@example.com|
|Radboud University Medical Centre||Recruiting|
|Principal Investigator:||M Verbeek, PhD, MSc||Radboud University|
|Principal Investigator:||B Bloem, Prof, MD||Radboud University|